Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
862 TLR9 agonism promotes cytotoxic T cell persistence and myeloid remodeling when combined with radiation therapy and PD-1 blockade in oligometastatic prostate cancer patients
Compose a Response to This Article
Other responses
No responses have been published for this article.
